Grundläggande statistik
| LEI | 8945006FVE3FLKX9BN50 |
| CIK | 1892500 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Clearmind Medicine Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 7, 2025 |
Exhibit 99.1 Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therap |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 5, 2025 |
Exhibit 99.1 Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinica |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| July 30, 2025 |
Exhibit 99.1 Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease Vancouver, Canada, July 28, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to so |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| July 29, 2025 |
Exhibit 99.1 www.ClearmindMedicine.com Novel Psychedelics for Treating Addictions, Obesity & Mental Health Corporate and Science Presentation | July 2025 NASDAQ: CMND FSE: CWY0 Clearmind Medicine Inc. Clearmind Medicine Inc. Page 2 All statements in this presentation, other than those relating to historical facts, are "forward-looking statements . ” Forward - looking statements contained in this p |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| July 15, 2025 |
Exhibit 99.1 Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated h |
|
| July 3, 2025 |
Exhibit 99.1 Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to sol |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 30, 2025 |
Exhibit 99.1 Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeu |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 27, 2025 |
Exhibit 99.1 Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated hea |
|
| June 23, 2025 |
Exhibit 99.1 Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated h |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 12, 2025 |
Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three and Six Months Ended April 30, 2025 This Management’s Discussion and Analysis (“MD&A”) of Clearmind Medicine Inc. (“Clearmind” or the “Company”), prepared as of Jun |
|
| June 12, 2025 |
As filed with the Securities and Exchange Commission on June 12, 2025. As filed with the Securities and Exchange Commission on June 12, 2025. Registration No. 333-276913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 6 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 12, 2025 |
Exhibit 99.1 Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated h |
|
| June 12, 2025 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) April 30, October 31, 2025 2024 Assets Current assets Cash and cash equival |
|
| June 5, 2025 |
Exhibit 99.1 Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FS |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| May 12, 2025 |
Exhibit 99.1 Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a cl |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 25, 2025 |
Exhibit 99.1 Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve maj |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 23, 2025 |
Exhibit 99.1 Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites The Company is now preparing for the enrollment of the first patient to receive Clearmind’s innovative treatment as part of the trial Vancouver, Canada, April 23, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the |
|
| April 17, 2025 |
Clearmind Medicine Receives Notice of Allowance for Unites States Patent Covering Binge Behavior Exhibit 99.1 Clearmind Medicine Receives Notice of Allowance for Unites States Patent Covering Binge Behavior Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health probl |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 10, 2025 |
Exhibit 99.1 Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solv |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 8, 2025 |
Exhibit 99.1 Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived th |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 1, 2025 |
Exhibit 99.1 Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE |
|
| March 24, 2025 |
Exhibit 99.1 Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics t |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| March 19, 2025 |
Exhibit 99.1 Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and |
|
| March 18, 2025 |
6-K 1 ea0234590-6kclearmind.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 |
|
| March 18, 2025 |
EX-99.1 2 ea023459001ex99-1clearmind.htm PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES INITIATION OF FIRST IN HUMAN CLINICAL TRIAL WITH CMND-100 IN ALCOHOL USE DISORDER PATIENTS" Exhibit 99.1 Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients Study represents the first clinical application of CMND-100, the Company’s proprie |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| March 13, 2025 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended January 31, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) January 31, October 31, 2025 2024 Assets Current assets Cash and cash equivalents |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025. As filed with the Securities and Exchange Commission on March 13, 2025. Registration No. 333-276913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other |
|
| March 13, 2025 |
Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three Months Ended January 31, 2025 (Expressed in United States Dollars) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three Months Ended January 31, 2025 This Management’s Discussion and Analysis (“MD&A”) of Clearmind Medicine Inc. (“Clearmind” or the “Company”), prepared as of March 13, 2025, |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| March 10, 2025 |
Exhibit 99.1 Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major u |
|
| February 4, 2025 |
Exhibit 99.1 Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-trea |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| January 22, 2025 |
Exhibit 4.18 License Agreement This License Agreement (the “Agreement”), effective as of January 15th 2024 (the “Effective Date”), is entered into by and between BIRAD Research and Development Company Ltd., a company formed under the laws of Israel, having a place of business at Bar Ilan University, Ramat Gan 5290002, Israel (“BIRAD”) and Clearmind Medicine Inc., a company formed under the laws of |
|
| January 22, 2025 |
CLEARMIN MEDICINE INC. (THE “COMPANY”) INSIDER TRADING AND BLACKOUT PERIOD POLICY Exhibit 11.1 CLEARMIN MEDICINE INC. (THE “COMPANY”) INSIDER TRADING AND BLACKOUT PERIOD POLICY PURPOSE The Company is a Canadian reporting issuer whose common shares trade on the Nasdaq (the “Exchange”). As such, trades in the Company’s securities1 are subject to Canadian rules and regulations, as well as the rules and regulations of the Exchanges (collectively, “securities laws”). Securities laws |
|
| January 22, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended October 31, 2024 (the “Report”) by Clearmind Medicine Inc. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with th |
|
| January 22, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-275991, 333-270859, and 333-273293 on Form F-3 and Registration Statement No. 333-283695 on Form S-8 of our report dated January 22, 2025, relating to the financial statements of Clearmind Medicine Inc., appearing in this Annual Report on Form 20-F f |
|
| January 22, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended October 31, 2024 (the “Report”) by Clearmind Medicine Inc. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with th |
|
| January 22, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Alan Rootenberg, certify that: 1. I have reviewed this annual report on Form 20–F of Clearmind Medicine Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whic |
|
| January 22, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dr. Adi Zuloff-Shani, certify that: 1. I have reviewed this annual report on Form 20–F of Clearmind Medicine Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| January 22, 2025 |
Exhibit 4.20 LICENSE AGREEMENT This License Agreement (the “Agreement”) is made in Jerusalem this 31st day of March, 2024 (the “Effective Date”), by and between: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the first part; and CLEARMIND MEDICINE INC., a company organized und |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| January 22, 2025 |
Exhibit 4.19 LICENSE AGREEMENT This License Agreement (the “Agreement”) is made in Jerusalem this 31 day of March, 2024 (the “Effective Date”), by and between: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the first part; and CLEARMIND MEDICINE INC., a company organized under |
|
| January 22, 2025 |
As filed with the Securities and Exchange Commission on January 22, 2025. As filed with the Securities and Exchange Commission on January 22, 2025. Registration No. 333-276913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or oth |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| January 7, 2025 |
Clearmind Medicine Announces Shareholders Meeting Results Exhibit 99.1 Clearmind Medicine Announces Shareholders Meeting Results Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of |
|
| January 6, 2025 |
Exhibit 99.1 Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve m |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| January 2, 2025 |
Exhibit 99.1 Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2025 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| December 26, 2024 |
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial Exhibit 99.1 Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| December 9, 2024 |
OMNIBUS STOCK AWARD PLAN SECTION 1 DEFINITIONS AND INTERPRETATION Exhibit 99.1 OMNIBUS STOCK AWARD PLAN SECTION 1 DEFINITIONS AND INTERPRETATION Definitions As used herein, unless there is something in the subject matter or context inconsistent therewith, the following terms shall have the meanings set forth below: (a) “Sub-Plan for Award Holders in Israel” means the Sub Plan, a copy of which is attached hereto as Appendix “A” for Award Holders who are resident |
|
| December 9, 2024 |
As filed with the Securities and Exchange Commission on December 9, 2024 As filed with the Securities and Exchange Commission on December 9, 2024 Registration No. |
|
| December 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Clearmind Medicine Inc. |
|
| December 6, 2024 |
Exhibit 99.1 CLEARMIND MEDICINE INC. MANAGEMENT INFORMATION CIRCULAR For the Annual and Special Meeting of Shareholders to be held on January 6, 2025 December 1, 2024 Table of Contents NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS 2 GENERAL PROXY INFORMATION 5 Solicitation of Proxies 5 Appointment of Proxies 5 Revocability of Proxy 5 Exercise of Discretion by Proxy 6 Voting by Beneficial Sh |
|
| December 6, 2024 |
Exhibit 99.2 |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| December 6, 2024 |
Exhibit 99.4 |
|
| December 6, 2024 |
Exhibit 99.5 Date: December 6, 2024 RE: Meeting of the shareholders of Clearmind Medicine Inc. to be held on January 6, 2025 (the “Meeting”) I, Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine Inc., hereby certify that: (a) arrangements have been made to have proxy related materials for the Meeting sent in compliance with National Instrument 54-101 (the “Instrument”), to all |
|
| December 6, 2024 |
Exhibit 99.3 |
|
| November 20, 2024 |
Subject: CLEARMIND MEDICINE INC. Exhibit 99.1 November 20, 2024 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: CLEARMIND MEDICINE INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual and Special Meeting Record Date for Notice of Meeting |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| November 14, 2024 |
Iroquois Capital Management, LLC SC 13G/A 1 c110567sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Clearmind Medicine Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 1850532047 (CUSIP Number) |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| October 10, 2024 |
FDA approval for the IND submission to conduct its trial already secured Exhibit 99.1 Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and deve |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of prin |
|
| September 24, 2024 |
As filed with the Securities and Exchange Commission on September 24, 2024. As filed with the Securities and Exchange Commission on September 24, 2024. Registration No. 333-276913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or o |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| September 16, 2024 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) July 31, October 31, 2024 2023 Assets Current assets Cash and cash equivale |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of prin |
|
| September 16, 2024 |
Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three and Nine Months Ended July 31, 2024 (Expressed in United States Dollars) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three and Nine Months Ended July 31, 2024 This Management’s Discussion and Analysis (“MD&A”) of Clearmind Medicine Inc. (“Clearmind” or the “Company”), prepared as of Sep |
|
| September 16, 2024 |
Exhibit 99.1 Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of prin |
|
| September 12, 2024 |
Exhibit 99.1 Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on |
|
| September 6, 2024 |
Exhibit 99.1 Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stag |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of prin |
|
| August 29, 2024 |
Exhibit 99.1 Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 21, 2024 |
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment Exhibit 99.1 Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced |
|
| August 20, 2024 |
Exhibit 99.1 www.ClearmindMedicine.com Creating an Alternative to Alcohol Corporate Presentation | 2024 NASDAQ: CMND FSE: CWY0 Clearmind Medicine Inc. Clearmind Medicine Inc. P a ge 2 All statements in this presentation, other than those relating to historical facts, are "forward - looking statements . ” Forward - looking statements contained in this presentation include, but are not limited to, s |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 16, 2024 |
Exhibit 99.1 Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutic |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princip |
|
| August 6, 2024 |
Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug Exhibit 99.1 Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health probl |
|
| July 23, 2024 |
As filed with the Securities and Exchange Commission on July 23, 2024. As filed with the Securities and Exchange Commission on July 23, 2024. Registration No. 333-276913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| July 19, 2024 |
Exhibit 99.1 Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major u |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| July 16, 2024 |
Exhibit 99.1 Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treat |
|
| July 16, 2024 |
Exhibit 99.2 Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics t |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 28, 2024 |
PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated March 22, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-276913 1,500,000 Common Shares This prospectus supplement updates, amends and supplements the prospectus dated March 22, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-276913 |
|
| June 28, 2024 |
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment Exhibit 99.1 Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, ann |
|
| June 13, 2024 |
Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three and Six Months Ended April 30, 2024 (Expressed in United States Dollars) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three and Six Months Ended April 30, 2024 This Management’s Discussion and Analysis (“MD&A”) of Clearmind Medicine Inc. (“Clearmind” or the “Company”), prepared as of Jun |
|
| June 13, 2024 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) April 30, October 31, 2024 2023 Assets Current assets Cash and cash equival |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 13, 2024 |
Exhibit 99.1 Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treat |
|
| May 10, 2024 |
Exhibit 99.1 Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and develop |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| May 7, 2024 |
Exhibit 99.1 Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated hea |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| April 30, 2024 |
Clearmind Applies to Cease Being a Reporting Issuer in Canada Exhibit 99.1 Clearmind Applies to Cease Being a Reporting Issuer in Canada Vancouver, Canada, April 30, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWYO) (“Clearmind” or the “Company”), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 17, 2024 |
Exhibit 99.1 Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeut |
|
| April 10, 2024 |
Exhibit 99.1 Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| April 9, 2024 |
Clearmind Medicine CEO Issues Letter to Shareholders Exhibit 99.1 Clearmind Medicine CEO Issues Letter to Shareholders Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today provided the following letter to s |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| March 27, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dr. Adi Zuloff-Shani, certify that: 1. I have reviewed this annual report on Form 20–F/A of Clearmind Medicine Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances und |
|
| March 27, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended October 31, 2023 (the “Report”) by Clearmind Medicine Inc. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| March 27, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Alan Rootenberg, certify that: 1. I have reviewed this annual report on Form 20–F/A of Clearmind Medicine Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| March 27, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended October 31, 2023 (the “Report”) by Clearmind Medicine Inc. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A (Amendment No. |
|
| March 27, 2024 |
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression Exhibit 99.1 Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announc |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024. As filed with the Securities and Exchange Commission on March 20, 2024. Registration No. 333-276913 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| March 19, 2024 |
Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three Months Ended January 31, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three Months Ended January 31, 2024 This Management’s Discussion and Analysis (“MD&A”) of Clearmind Medicine Inc. (“Clearmind” or the “Company”), prepared as of Mar |
|
| March 19, 2024 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended January 31, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) January 31, October 31, 2024 2023 Assets Current assets Cash and cash equivalents |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A (Amendment No. |
|
| March 18, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference therein of our audit report dated March 8, 2022 (except as to Note 1(c) which is as of October 19, 2022), included in its Annual Report on Form 20-F for the year ended October 31, 2023, filed with the Securities and Exchange Commission, in the Registration Statements on Form F-3 (Regi |
|
| March 18, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements on Form F-3 (No. 333-275991, 333-270859, and 333-273293) of our report dated January 29, 2024 (March 18, 2024, as to the November 28, 2023 reverse share split described in Note 1c and the change in presentation currency discussed in Note 1d), relating to the |
|
| March 18, 2024 |
March 18, 2024 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jenn Do Vanessa Robertson Re: Clearmind Medicine Inc. Form 20-F for the fiscal year ended October 31, 2023 Filed January 29, 2024 File No. 001-41557 Dear Ms. Do: On behalf of Clearmind Medicine Inc. (the “Company”), we are writing to submit the |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| March 13, 2024 |
Exhibit 99.1 Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treate |
|
| February 27, 2024 |
New patent applications build upon Clearmind’s broad IP protection in the psychedelic space Exhibit 99.1 Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds New patent applications build upon Clearmind’s broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focus |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| February 23, 2024 |
Exhibit 99.1 Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder For the first time, patients with alcohol use disorder will receive the company’s unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biot |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| February 20, 2024 |
Exhibit 99.1 Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treate |
|
| February 14, 2024 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 February 14, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK 0001892500) Registration Statement No. 333-276913 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Clearmind Medicine Inc. (the “R |
|
| February 14, 2024 |
CA:CMND / Clearmind Medicine Inc. / AdvisorShares Trust Passive Investment SC 13G 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Clearmind Medicine Inc. (Name of Issuer) common shares, no par value (Title of Class of Securities) 18505340 |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| February 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) Clearmind Medicine Inc. |
|
| February 7, 2024 |
As filed with the Securities and Exchange Commission on February 7, 2024. As filed with the Securities and Exchange Commission on February 7, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or orga |
|
| February 6, 2024 |
SC 13G/A 1 ea192874-13ga1intraclear.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Clearmind Medicine Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 185053402 (CUSIP Number) December 31, 2023 (Date of Event Which Requires |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| February 5, 2024 |
Exhibit 99.1 Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-tr |
|
| February 1, 2024 |
Exhibit 99.1 Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center The licensing agreement refers to the company’s dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| January 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements on Form F-3 (No. 333-275991, 333-270859, and 333-273293) of our report dated January 29, 2024, relating to the financial statements of Clearmind Medicine Inc., appearing in this Annual Report on Form 20-F of Clearmind Medicine Inc. for the year ended October |
|
| January 29, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dr. Adi Zuloff-Shani, certify that: 1. I have reviewed this annual report on Form 20–F of Clearmind Medicine Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| January 29, 2024 |
Re: Clearmind Medicine Inc. (the “Company”) Exhibit 16.1 Re: Clearmind Medicine Inc. (the “Company”) This letter will confirm that we reviewed Item 16F of the Company’s Form 20-F, which we understand will be filed with the United States Securities and Exchange Commission, on or about January 29, 2024, captioned “Change in the Registrant’s Certifying Accountant” and that we agree with the statements made therein as they relate to Saturna Gro |
|
| January 29, 2024 |
Exhibit 2.1 DESCRIPTION OF SECURITIES Description of Common Shares General This section summarizes the material rights of shareholders of Clearmind Medicine Inc. (“CMND”) under the Business Corporations Act (British Columbia) (the “BCA”) and the material provisions of the articles of CMND (the “Articles”). On September 30, 2022, our shareholders approved a one-for-30 reverse split of our issued an |
|
| January 29, 2024 |
Exhibit 4.7 Clearmind Medicine, Inc. Executive Officer Clawback Policy Approved by the Compensation Committee of the Board of Directors on November 13, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Clearmind Medicine, Inc. and any of its direct or indirect subsidiaries (the “Company”) will be required to repa |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| January 29, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended October 31, 2023 (the “Report”) by Clearmind Medicine Inc. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with th |
|
| January 29, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended October 31, 2023 (the “Report”) by Clearmind Medicine Inc. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with th |
|
| January 29, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Alan Rootenberg, certify that: 1. I have reviewed this annual report on Form 20–F of Clearmind Medicine Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whic |
|
| January 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference therein of our audit report dated March 8, 2022 (except as to Note 1(c) which is as of October 19, 2022), included in its Annual Report on Form 20-F for the year ended October 31, 2023, filed with the Securities and Exchange Commission, in the Registration Statements on Form F-3 (Regi |
|
| January 22, 2024 |
CA:CMND / Clearmind Medicine Inc. / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Clearmind Medicine Inc (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 1850532047 (CUSIP Number) January 11, 2024 (Date of Event |
|
| January 18, 2024 |
As filed with the Securities and Exchange Commission on January 18, 2024 As filed with the Securities and Exchange Commission on January 18, 2024 Registration No. |
|
| January 16, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 11, 2024, between Clearmind Medicine Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| January 16, 2024 |
PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES CLEARMIND MEDICINE INC. Exhibit 10.3 PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES CLEARMIND MEDICINE INC. Warrant Shares: [●] Initial Exercise Date: January 11, 2024 Issue Date: January 16, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions her |
|
| January 16, 2024 |
Exhibit 10.5 January 11, 2024 PERSONAL AND CONFIDENTIAL Dr. Adi Adi Zuloff-Shani, Chief Executive Officer Clearmind Medicine Inc. Re: CMND | Registered Direct and PIPE Offering | Dear Dr. Adi Zuloff-Shani: The purpose of this placement agent agreement (“Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis |
|
| January 16, 2024 |
WARRANT TO PURCHASE COMMON SHARES CLEARMIND MEDICINE INC. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 16, 2024 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 11, 2024, between Clearmind Medicine Inc., a British Columbia corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti |
|
| January 16, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-275991 PROSPECTUS SUPPLEMENT (To prospectus dated December 26, 2023) 1,468,000 Common Shares Pre-Funded Warrants to Purchase up to 32,000 Common Shares CLEARMIND MEDICINE INC. We are offering pursuant to this prospectus supplement and the accompanying prospectus (i) 1,468,000 Common Shares, no par value, or the Common Shares, at an offering pri |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2024 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| January 10, 2024 |
Clearmind Medicine Completed Type A Meeting with the FDA Exhibit 99.1 Clearmind Medicine Completed Type A Meeting with the FDA Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has compl |
|
| December 26, 2023 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 December 26, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK 0001892500) Registration Statement No. 333-275991 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Clearmind Medicine Inc. (the “R |
|
| December 22, 2023 |
As filed with the Securities and Exchange Commission on December 22, 2023 As filed with the Securities and Exchange Commission on December 22, 2023 Registration No. |
|
| December 14, 2023 |
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards Exhibit 99.1 Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been Cured Tel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| December 11, 2023 |
As filed with the Securities and Exchange Commission on December 11, 2023 As filed with the Securities and Exchange Commission on December 11, 2023 Registration No. |
|
| December 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Clearmind Medicine Inc. |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| November 28, 2023 |
Exhibit 99.1 Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite Tel Aviv, Israel / Vancouver, Canada, Nov. 28, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine |
|
| November 21, 2023 |
Clearmind Medicine Announces 1-for-30 Reverse Share Split Exhibit 99.1 Clearmind Medicine Announces 1-for-30 Reverse Share Split Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel ps |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| November 17, 2023 |
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance Exhibit 99.1 Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance As part of the Company’s plan for recompliance, the Company’s shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, November 17, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| November 15, 2023 |
Clearmind Medicine Announces Shareholders Meeting Results Exhibit 99.1 Clearmind Medicine Announces Shareholders Meeting Results Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that |
|
| October 24, 2023 |
Exhibit 99.1 CLEARMIND MEDICINE INC. MANAGEMENT INFORMATION CIRCULAR For the Annual and Special Meeting of Shareholders to be held on November 14, 2023 October 9, 2023 Table of Contents NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS 1 GENERAL PROXY INFORMATION 3 Solicitation of Proxies 3 Appointment of Proxies 3 Revocability of Proxy 4 Exercise of Discretion by Proxy 4 Voting by Beneficial S |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2023 Commission file number: 001-41557 CLEARMIND MEDICINE INC. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princi |
|
| October 24, 2023 |
Exhibit 99.3 CL 1 |
|
| October 24, 2023 |
Exhibit 99.2 CLEARMIND MEDICIN E INC. Security Class Holder Account Number Form of Proxy - Annual and Special Meeting to be held on November 14, 2023 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any ad |
|
| October 24, 2023 |
Exhibit 99.4 |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| September 18, 2023 |
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering Exhibit 99.1 Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced th |
|
| September 18, 2023 |
Filed pursuant to Rule 424(b)(4) Registration No. 333-273293 PROSPECTUS 6,775,000 Common Shares 725,000 Pre-Funded Warrants to Purchase 725,000 Common Shares 7,500,000 Common Warrants to Purchase 7,500,000 Common Shares (and 7,500,000 Common Shares issuable upon the exercise of the Common Warrants) Clearmind Medicine Inc. We are offering 6,775,000 Common Shares of Clearmind Medicine Inc. at a publ |
|
| September 18, 2023 |
Clearmind Medicine Closes US$2.25 Million Public Offering Exhibit 99.2 Clearmind Medicine Closes US$2.25 Million Public Offering Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the closing of i |
|
| September 13, 2023 |
As filed with the Securities and Exchange Commission on September 13, 2023. As filed with the Securities and Exchange Commission on September 13, 2023. Registration No. 333-273293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 2 To FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdicti |
|
| September 13, 2023 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) July 31, 2023 October 31, 2022 Assets Current assets Cash and cash equivale |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| September 13, 2023 |
Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three and Nine Months Ended July 31, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three and Nine Months Ended July 31, 2023 This Management’s Discussion and Analysis (“MD&A”) of Clearmind Medicine Inc. (“Clearmind” or the “Company”), prepar |
|
| September 13, 2023 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 September 13, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK: 0001892500) Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Clearmind Medicine Inc. (the |
|
| September 6, 2023 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 September 6, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK: 0001892500) Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our lette |
|
| September 6, 2023 |
Exhibit 99.1 Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-d |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of princ |
|
| September 5, 2023 |
CMNDD / Clearmind Medicine Inc / Medigus Ltd. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Act of 1934 (Amendment No. 1) Clearmind Medicine Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 1850532047 (CUSIP Number) April 6, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| September 5, 2023 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 September 5, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK: 0001892500) Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Clearmind Medicine Inc. (the “ |
|
| August 14, 2023 |
Exhibit 99.1 Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major und |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principa |
|
| August 1, 2023 |
Exhibit 99.1 Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-deriv |
|
| July 27, 2023 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 July 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK: 0001892500) Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our letter, f |
|
| July 25, 2023 |
As filed with the Securities and Exchange Commission on July 25, 2023. As filed with the Securities and Exchange Commission on July 25, 2023. Registration No. 333-273293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 To FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of |
|
| July 25, 2023 |
Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 July 25, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Clearmind Medicine Inc. (CIK: 0001892500) Registration Statement No. 333-273293 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Clearmind Medicine Inc. (the “Regi |
|
| July 17, 2023 |
As filed with the Securities and Exchange Commission on July 17, 2023. As filed with the Securities and Exchange Commission on July 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organiz |
|
| July 17, 2023 |
COMMON SHARE PURCHASE WARRANT CLEARMIND MEDICINE INC. Exhibit 4.2 COMMON SHARE PURCHASE WARRANT CLEARMIND MEDICINE INC. Warrant Shares: Initial Exercise Date: [ ], 2023 Issue Date: [ ], 2023 CUSIP: ISIN: THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder,” provided that a “Holder” shall include, if the Warrants are held in “street name,” a Participant, any designee appointed by such |
|
| July 17, 2023 |
PRE-FUNDED COMMON SHARES PURCHASE WARRANT Clearmind Medicine Inc. Exhibit 4.1 PRE-FUNDED COMMON SHARES PURCHASE WARRANT Clearmind Medicine Inc. Warrant Shares: [●] Initial Exercise Date: [●], 2023 CUSIP: ISIN: Issuance Date: [●], 2023 THIS PRE-FUNDED COMMON SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●], or its registered assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditi |
|
| July 17, 2023 |
AEGIS CAPITAL CORP. July __ 2023 Exhibit 1.1 AEGIS CAPITAL CORP. July 2023 PERSONAL AND CONFIDENTIAL Dr. Adi Zuloff-Shani, Chief Executive Officer Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Re: CMND Secondary Public Offering Dear Dr. Zuloff-Shani: The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) wi |
|
| July 17, 2023 |
Exhibit 4.3 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [●], 2023 (the “Issuance Date”) is between Clearmind Medicine Inc., a British Columbia corporation (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company (collectively with Compu |
|
| July 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) Clearmind Medicine Inc. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| July 11, 2023 |
Exhibit 99.1 Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-d |
|
| June 16, 2023 |
Exhibit 99.1 Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome The treatment combines Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc’s Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™ Tel Aviv, Israel / Vancouver, Canada, June 16, 2023 (GLOBE NEWSWIRE |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal |
|
| June 14, 2023 |
Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) April 30, 2023 October 31, 2022 Assets Current assets Cash and cash equival |
|
| June 14, 2023 |
EX-99.2 3 ea180126ex99-2clearmind.htm MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FOR THE THREE AND SIX MONTHS ENDED APRIL 30, 2023 Exhibit 99.2 CLEARMIND MEDICINE INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three and Six Months Ended April 30, 2023 Expressed in United States Dollars (Unaudited) CLEARMIND MEDICINE INC. Management’s Discussion and Analysis For the Three and Six Months Ended |
|
| May 22, 2023 |
Exhibit 99.1 Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeut |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal e |
|
| May 19, 2023 |
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, t |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal e |
|
| May 12, 2023 |
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder Exhibit 99.1 Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder IMCA medical center’s ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused o |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal e |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-41557 Clearmind Medicine Inc. (Translation of registrant’s name into English) 101 – 1220 West 6th Avenue Vancouver, British Columbia (Address of principal e |
|
| May 8, 2023 |
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam Exhibit 99.1 Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery a |
